Gil Price, M.D. - Chairman of Scientific Advisory Board

Experienced biotech executive and entrepreneur with depth of expertise across clinical asset investment strategy, evaluation, financing and execution. Additional leadership experience within R&D, Medical, and Strategy corporate functions.

Dr. Price was previously responsible for the strategic and tactical management of all business at Drug Safety Solutions. After a successful 20-year history, Drug Safety Solutions was acquired in June 2017 by Linden Capital Partners. Dr. Price now functions as the Chief Medical Officer for the global ProPharma Group, a Linden subsidiary.

Over the years Dr. Price has served on multiple corporate boards, including public, private, and not-for-profit. His board duties have included the Chairman’s role on Compensation and Governance as well as a member’s role on Audit. He has served on boards that report to; TSX, NYSE American, and NASDAQ. In his recent most recent experience, Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) he serves on Compensation, Governance, and Business Development. In his previous role with Sarepta Therapeutics NASDAQ: SRPT, he helped to guide the company transition from $80 million market (2008) to it’s current $8.4 billion market cap (2019).